Praxbind is the Pradaxa Antidote
The FDA granted fast track approval to Boeheringer’s latest drug offering, Praxbind. This new drug is the long-awaited antidote to new gen anticoagulant, Pradaxa. Preliminary clinical trials suggest an 89% efficacy rate within four hours of IV administration. This could be a life-saving tool for medical providers caring for patients on Pradaxa, a drug known for its high risk of uncontrollable and even fatal belleding events.